A Phase 3 interventional study of Radiprodil and Placebo in GRIN-related Neurodevelopmental Disorder, sponsored by GRIN Therapeutics, Inc.. Recruiting at 62 sites in 13 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by GRIN Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Neurodevelopmental Disorders with a site in United States — 36 open to participants now, 52 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.
Among the 99 studies in Neurodevelopmental Disorders with a site in United States, this one is the 29th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 21 of the 51 other live ones, and was the 90th registered.
353 studies on the registry are indexed under Neurodevelopmental Disorders; 142 are open to participants now.
Browse Neurodevelopmental Disorders studies →36 of the 99 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 6 mo+
Life University · Sites in United States
Ages 8+
UCB Biopharma SRL · Sites in United States, France, Spain
Ages up to 17
Healing Hope International · Sites in United States
Ages 4–12
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Sites in United States
Ages 1 mo–24 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 1996; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 88 across 217 interventional studies indexed under Neurodevelopmental Disorders.
Median enrollment 100 across the 60 interventional studies, 166 across the 39 observational. Of the 43 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 99 have an industry lead sponsor. The 10 most frequent:
GRIN Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
GRIN Therapeutics, Inc. has 1 study filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
19 of the studies in Neurodevelopmental Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06915480Phase 3Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Reducing Missed Appointments | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT03770832Shirley Ryan AbilityLabWearable Sensors and Video Recordings to Monitor Motor Development | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 99 studies in Neurodevelopmental Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant.
This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort).
Participants in each cohort will be randomized 1:1 to receive active drug (radiprodil) or matching placebo (Part A). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.
The placebo-controlled portion is expected to be approximately 16 weeks for participants in Phase 3 Cohort 1 and 28 weeks for participants in Phase 3 Cohort 2.
The study will evaluate the effect of radiprodil on seizures and non-seizure symptoms and assess safety.
Participants are assigned in a 1:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Open-Label Extension, Part B. The dosing regimen includes a fixed titration schedule over 4 weeks.
This study is divided into the following parts:
Part A: Randomized, double-blind, placebo-controlled
Part B: Open-label safety follow-up period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A, Participant:
Part B:
- Participant has completed Part A and is eligible to continue study participation according to the judgement of the investigator and sponsor.
Exclusion Criteria:
PART A, Participant:
Part B:
- Participant has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liquid suspension of radiprodil, at varying concentrations depending on participant's weight. The following dose-escalation regimen (twice daily \[BID\]) will be used: Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose.
Drug: Radiprodil
Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen.
Drug: Placebo
Radiprodil oral suspension
Placebo-to-match radiprodil oral suspension
Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Countable motor seizures (CMS)
Time frame: 12 weeks
Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)
Time frame: 24 weeks
Part B - Open-Label Extension: Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)
Time frame: Average of 2 years
Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Proportion of participants with ≥50% reduction in CMS
Time frame: 12 weeks
Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): CMS-free days
Time frame: 12 weeks
Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): GRIN-NDD-specific Clinical Global Impression - Change [CGI-C] scale
Time frame: 12 weeks
Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Aberrant Behavior Checklist-Community (ABC-2C) irritability subscale
Time frame: 12 weeks
Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Vineland Adaptive Behavior Scale 3rd edition (VABS-3) daily living personal subdomain
Time frame: 12 weeks
Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): GRIN-CGI-C scale
Time frame: 24 weeks
Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): ABC-2C irritability subscale
Time frame: 24 weeks
Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): VABS-3 daily living personal subdomain
Time frame: 24 weeks
PART B - Open-Label Extension: CMS frequency
Time frame: average of 2 years
PART B - Open-Label Extension: CMS-free days
Time frame: average of 2 years
PART B - Open-Label Extension: ABC-2C irritability subscale
Time frame: average of 2 years
PART B - Open-Label Extension: VABS-3 daily living personal subdomain score
Time frame: average of 2 years
PART B - Open-Label Extension: GRIN-CGI-C scale
Time frame: average of 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Radiprodil
Neurodevelopmental Disorders →
GRIN Therapeutics, Inc.